Earnings
Aurora Spine Corporation Announces Record Fourth Quarter and FY25 Financial Results
Aurora Spine Posts Record Revenue as Turnaround Strategy Takes Hold
Executive Summary
- Event: Q4 and Fiscal Year 2025 Financial Results released on April 30, 2026.
- Revenue Performance: Q4 2025 revenue reached $5.02 million, a record high exceeding the previous quarter ($4.43M) and year-over-year comparison ($4.70M). Full Year 2025 revenue totaled $18.4 million.
- Profitability Metrics: EBITDAC turned positive at $301,112 for Q4 (vs loss of $320k in Q4 2024). Full year EBITDAC was $587,532. Gross margins improved to 62.4% in Q4.
- Net Income: Net loss narrowed significantly to $(40,702) for Q4 compared to $(652,696) in the prior year period. Full year net loss was $(731,120).
- Product Updates: Zip sales increased 23% YoY. Aurora Biologics launched late 2025 contributing $0.2 million. Apollo plate is in production; DEXA-C and DEXA-L offerings are planned for future rollout.
- Balance Sheet: Cash position stands at $896,713 as of Dec 31, 2025. Accounts Receivable are high at $3.31 million. Inventory is valued at $3.24 million.
Material Impact
- Operational Validation: The news confirms the positive trajectory established in Q3 2025 (which also reported positive EBITDAC). This reduces execution risk regarding the company's ability to generate cash flow from operations before interest and taxes.
- Revenue Milestone: Crossing the $5 million quarterly revenue threshold is a tangible milestone for a small-cap medical device firm, suggesting product adoption is accelerating beyond initial expectations.
- Cash Flow Reality Check: Despite EBITDAC positivity, the company remains in a net loss position. The cash balance ($896k) is low relative to quarterly operating expenses (~$3.15M), indicating potential liquidity pressure if working capital (receivables/inventory) does not convert quickly.
- Market Reaction Context: Historical price data shows the stock has been range-bound between $0.25 and $0.36 over the last year, with a recent drift toward the lower end ($0.28). This suggests the market may have already priced in the "path to profitability" narrative following Q3 results, making this confirmation routine rather than a surprise catalyst.
- Debt Relief: The March 2026 loan amendment (interest rate cut from 9% to 4.5%) materially reduces cash burn on debt service, supporting the improved EBITDAC figures.
ASG · Price
Company Overview
- Overview: Aurora Spine Corporation is a medical device company focused on spinal fusion solutions. They have pivoted towards proprietary products (Zip, Hydra A.E.R.O., DEXA) to improve margins compared to distributor models.
- Flagship Project: The Zip system and the new Biologics division (Aurora Biologics) are central to growth. The Apollo plate is currently in production with future DEXA cervical/lumbar applications planned.
- Development Stage: Commercial stage with revenue generation, transitioning from distributor-dependent sales to direct proprietary product sales to enhance gross margins (now >60%).
More from Aurora Spine Corporation
May 28, 2026 · 07:15